Cerus Corporation (CERS) Announces INTERCEPT Blood System for Platelets Regulatory Submission for Approval in South Africa  
9/4/2012 10:16:45 AM

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) announced today that Ilex, Cerus’ exclusive distributor for South Africa, has submitted a regulatory dossier for approval of the INTERCEPT Blood System for platelets under a fast track designation by the South African Medicines Control Council (MCC).